We are live on ! Find out more
SCM

Stonepine Capital Management Portfolio holdings

AUM $250M
1-Year Est. Return 77.6%
This Fund
S&P 500
This Quarter Est. Return
+38.99%
1 Year Est. Return
+77.6%
3 Year Est. Return
+198.76%
5 Year Est. Return
+226.15%
10 Year Est. Return
+1,976.54%
AUM
$51.6M
AUM Growth
-$42.9M
Cap. Flow
-$54.8M
Cap. Flow %
-106.19%
Top 10 Hldgs %
95.77%
Holding
29
New
3
Increased
1
Reduced
9
Closed
16

Top Buys

1
AVTX icon
Avalo Therapeutics
AVTX
+$1.13M
2
BIOR
Biora Therapeutics, Inc. Common Stock
BIOR
+$1.05M
3
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$649K
4
FRTX
Fresh Tracks Therapeutics, Inc. Common Stock
FRTX
+$174K

Top Sells

1
LGND icon
Ligand Pharmaceuticals
LGND
+$6.96M
2
AMRN
Amarin Corp
AMRN
+$5.25M
3
AFMD
Affimed
AFMD
+$4.74M
4
STML
Stemline Therapeutics, Inc.
STML
+$4.29M
5
OPNT
Opiant Pharmaceuticals, Inc. Common Stock
OPNT
+$3.65M

Sector Composition

1 Healthcare 96.24%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ISEE
1
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$14M 27.06%
2,739,641
+155,855
+6% +$649K
LGND icon
2
Ligand Pharmaceuticals
LGND
$6.08B
$10.3M 20.02%
148,128
-109,825
-43% -$6.96M
CTIC
3
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$4.72M 9.14%
4,068,191
-2,362,446
-37% -$2.5M
DMAC icon
4
DiaMedica Therapeutics
DMAC
$393M
$4.63M 8.97%
668,430
-156,867
-19% -$700K
GYRE icon
5
Gyre Therapeutics
GYRE
$675M
$3.21M 6.23%
73,005
-62,888
-46% -$2.95M
NEOS
6
DELISTED
Neos Therapeutics, Inc
NEOS
$3.05M 5.9%
4,447,026
-243,120
-5% -$193K
XOMA
7
DELISTED
Xoma
XOMA
$2.97M 5.75%
150,213
-58,387
-28% -$1.28M
APEN
8
DELISTED
Apollo Endosurgery, Inc.
APEN
$2.37M 4.58%
1,447,765
-236,096
-14% -$469K
CPIX icon
9
Cumberland Pharmaceuticals
CPIX
$102M
$2.25M 4.36%
676,592
-231,143
-25% -$840K
ADMS
10
DELISTED
Adamas Pharmaceuticals
ADMS
$1.94M 3.76%
757,704
-405,172
-35% -$1.19M
AVTX icon
11
Avalo Therapeutics
AVTX
$1.02B
$1.17M 2.27%
+156
New +$1.13M
BIOR
12
DELISTED
Biora Therapeutics, Inc. Common Stock
BIOR
$865K 1.68%
+385
New +$1.05M
FRTX
13
DELISTED
Fresh Tracks Therapeutics, Inc. Common Stock
FRTX
$147K 0.28%
+3,261
New +$174K
AFMD
14
DELISTED
Affimed
AFMD
– –
-300,000
Closed -$4.74M
AMRN
15
Amarin Corp
AMRN
$292M
– –
-65,655
Closed -$5.25M
CDTX
16
DELISTED
Cidara Therapeutics
CDTX
– –
-65,149
Closed -$3.23M
EOLS icon
17
Evolus
EOLS
$377M
– –
-822,960
Closed -$3.42M
RIGL icon
18
Rigel Pharmaceuticals
RIGL
$750M
– –
-1,000
Closed -$16K
OPNT
19
DELISTED
Opiant Pharmaceuticals, Inc. Common Stock
OPNT
– –
-380,948
Closed -$3.65M
SPNE
20
DELISTED
SeaSpine Holdings Corporation Common Stock
SPNE
– –
-253,131
Closed -$2.07M
HTGM
21
DELISTED
HTG Molecular Diagnostics, Inc. Common Stock
HTGM
– –
-5,515
Closed -$323K
AGTC
22
DELISTED
Applied Genetic Technologies Corporation
AGTC
– –
-586,969
Closed -$1.93M
ATRS
23
DELISTED
Antares Pharma, Inc.
ATRS
– –
-151,189
Closed -$357K
BXRX
24
DELISTED
Baudax Bio, Inc. Common Stock
BXRX
– –
-436
Closed -$1.51M
CHMA
25
DELISTED
Chiasma, Inc. Common Stock
CHMA
– –
-744,134
Closed -$2.72M
1
2

Similar funds

BIA
Bigelow Investment Advisors Portland, Maine $250M AUM 19.33% 1-Year Est. Return
TGP
TMT General Partner Hong Kong $250M AUM 6.05% 1-Year Est. Return
ER
EVR Research Richmond, Virginia $250M AUM 41.5% 1-Year Est. Return
FDDB
Fidelity D&D Bancorp Dunmore, Pennsylvania $249M AUM 18.9% 1-Year Est. Return
VM
VPR Management Houston, Texas $250M AUM 34.13% 1-Year Est. Return
PF
Parker Financial Silverdale, Washington $250M AUM 14.69% 1-Year Est. Return
SCM
Step Capital Management Singapore $249M AUM
CWM
Chicago Wealth Management Chicago, Illinois $251M AUM 45.31% 1-Year Est. Return

Stonepine Capital Management's Q2 2020 Portfolio in Review

As of Q2 2020, Stonepine Capital Management held 29 positions worth $51.6M, down 45% from $94.6M the previous quarter. Its ten largest holdings account for 96% of the portfolio.

Stonepine Capital Management withdrew a net $54.8M in Q2 2020, closing 16 positions and reducing 9 holdings. Its most notable exit was Amarin Corp, an estimated $5.25M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 91% a quarter earlier.

Against the trend, Stonepine Capital Management opened a new position in Avalo Therapeutics worth $1.17M.

  • Stonepine Capital Management's largest Q2 2020 buy was Avalo Therapeutics: 156 shares worth $1.17M.
  • Stonepine Capital Management added most to IVERIC bio, Inc. Common Stock in Q2 2020, an estimated $649K increase.
  • Stonepine Capital Management's biggest Q2 2020 reduction was Ligand Pharmaceuticals, cutting an estimated $6.96M.
  • Stonepine Capital Management fully exited Amarin Corp in Q2 2020, selling an estimated $5.25M.
  • Stonepine Capital Management's ten largest holdings make up 96% of its $51.6M portfolio in Q2 2020.
  • Stonepine Capital Management opened 3 new positions and closed 16 in Q2 2020.
  • Stonepine Capital Management's portfolio value fell 45% quarter-over-quarter to $51.6M.

Based on Stonepine Capital Management's 13F filing for Q2 2020, filed 13 Aug 2020.